Cite
HARVARD Citation
Pujol, J. et al. (n.d.). 1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. Annals of oncology. p. . [Online].